Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Evidence Of Lung Stem Cells In Adults

This article was originally published in Start Up

Executive Summary

Whether a range of organ-specific stem cells exists and can be harnessed for potential therapy is an open question, but encouragingly, researchers have now provided evidence of human lung-specific stem cells. In addition to their potential role in regenerative medicine of the lung, continuing research around the methods used to find these cells could be a starting point for the development of improved methods for identifying enriched or more potent organ-specific stem cell populations.

You may also be interested in...



Cancer Stem Cell Differentiation In Reverse, Spontaneously

Scientists have now shown that both normal and cancerous mammary cells may spontaneously "de-differentiate" into stem cells without any genetic manipulations. This apparently innate cellular plasticity suggests new possibilities for utilizing cultured cells both as a tool in the discovery of cancer therapies that target cancer stem cells and also as an autologous therapy in regenerative medicine.

Stem Cells: What's the Business Model?

The science of stem cells is progressing, slowly but surely, towards the ultimate goal of creating a therapeutic. The challenge is now largely economic: convincing investors that stem cells present a viable business opportunity.

Biotechs Choosing Brazil For Drug Development And Early Sales

Brazil has established an accelerated pathway for approval of drugs for ultra-rare diseases, encouraging development activity – but the definition of qualifying drugs is narrow. Expansion to include more treatments could boost clinical trials activity and companies’ overall development presence.

Topics

Related Companies

UsernamePublicRestriction

Register

SC092127

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel